Gastrointestinal stromal tumors, or GISTs, most commonly occur in the stomach or small intestine. GISTs with a certain type of mutation don’t respond to typical GIST therapies, and Ayvakit is the first drug approved to target the specific mutation, which occurs in about 10 percent of GISTs.
Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase that helps keep cancer cells from growing.
In clinical trials, almost 85 percent of patients saw tumor shrinkage with Ayvakit.
The drug was granted breakthrough therapy designation, fast track designation and orphan drug designation.
Read the full news release here.
More articles on pharmacy:
GAO report hits lax oversight of 340B drug program
Venture capitalist launches company to bring drug prices down
AMAG Pharmaceuticals replacing CEO, cutting 2 drugs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
